Achieve Life Sciences (ACHV) Competitors $2.97 -0.11 (-3.57%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$3.00 +0.03 (+1.01%) As of 08:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHV vs. VSTM, XOMA, EBS, LXRX, VNDA, CBIO, IRWD, CDXS, SGMO, and AGENShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Verastem (VSTM), XOMA Royalty (XOMA), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Sangamo Therapeutics (SGMO), and Agenus (AGEN). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Its Competitors Verastem XOMA Royalty Emergent Biosolutions Lexicon Pharmaceuticals Vanda Pharmaceuticals Crescent Biopharma Ironwood Pharmaceuticals Codexis Sangamo Therapeutics Agenus Achieve Life Sciences (NASDAQ:ACHV) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Which has more volatility & risk, ACHV or VSTM? Achieve Life Sciences has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Which has stronger valuation & earnings, ACHV or VSTM? Achieve Life Sciences has higher earnings, but lower revenue than Verastem. Verastem is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$39.83M-$1.46-2.03Verastem$10K52,985.94-$130.64M-$3.28-2.63 Do analysts recommend ACHV or VSTM? Achieve Life Sciences currently has a consensus target price of $14.67, indicating a potential upside of 393.83%. Verastem has a consensus target price of $13.29, indicating a potential upside of 54.31%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Verastem 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor ACHV or VSTM? In the previous week, Achieve Life Sciences had 8 more articles in the media than Verastem. MarketBeat recorded 13 mentions for Achieve Life Sciences and 5 mentions for Verastem. Achieve Life Sciences' average media sentiment score of 0.56 beat Verastem's score of 0.03 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ACHV or VSTM? 33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 2.1% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ACHV or VSTM more profitable? Achieve Life Sciences' return on equity of -193.49% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -193.49% -116.68% Verastem N/A -2,003.62%-119.85% SummaryAchieve Life Sciences beats Verastem on 12 of the 15 factors compared between the two stocks. Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.40M$2.55B$5.74B$10.39BDividend YieldN/A54.21%5.75%4.64%P/E Ratio-2.0323.2675.8226.11Price / SalesN/A716.05548.23124.93Price / CashN/A176.2437.5461.24Price / Book4.875.1412.396.30Net Income-$39.83M$32.95M$3.29B$271.03M7 Day Performance4.76%1.15%0.25%-0.20%1 Month Performance-4.81%4.94%2.79%5.77%1 Year Performance-33.11%0.55%60.56%27.62% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences2.1606 of 5 stars$2.97-3.6%$14.67+393.8%-32.2%$157.40MN/A-2.0320Positive NewsVSTMVerastem2.5543 of 5 stars$9.13+0.9%$13.29+45.5%+227.4%$556.98M$10K-2.7850XOMAXOMA Royalty4.2653 of 5 stars$37.16+1.3%$69.50+87.0%+36.8%$443.62M$28.49M-23.9710Insider TradeGap DownEBSEmergent Biosolutions4.6758 of 5 stars$8.16-0.7%$13.50+65.5%+47.2%$438.01M$1.04B3.332,420LXRXLexicon Pharmaceuticals2.094 of 5 stars$1.16-2.5%$3.23+178.0%-11.3%$432.45M$31.08M-3.52140VNDAVanda Pharmaceuticals4.0794 of 5 stars$4.75+5.8%$16.50+247.4%-0.4%$265.31M$198.77M-4.20290News CoveragePositive NewsCBIOCrescent Biopharma4.3183 of 5 stars$13.11+1.5%$25.60+95.3%N/A$252.58M$10K-0.3850IRWDIronwood Pharmaceuticals4.303 of 5 stars$1.44+2.1%$4.94+243.1%-67.7%$229.03M$351.41M-28.79220Positive NewsCDXSCodexis3.5193 of 5 stars$2.52+2.9%$11.00+336.5%-17.5%$221.15M$59.35M-3.04250SGMOSangamo Therapeutics2.8863 of 5 stars$0.55+0.9%$4.50+716.7%-26.0%$164.70M$57.80M-1.90480News CoveragePositive NewsAGENAgenus3.9042 of 5 stars$4.60+5.0%$14.50+215.2%-22.5%$139.57M$103.46M-0.64440News Coverage Related Companies and Tools Related Companies VSTM Alternatives XOMA Alternatives EBS Alternatives LXRX Alternatives VNDA Alternatives CBIO Alternatives IRWD Alternatives CDXS Alternatives SGMO Alternatives AGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHV) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
